Intuitive Surgical price target raised to $655 from $650 at Bernstein

Bernstein raised the firm’s price target on Intuitive Surgical (ISRG) to $655 from $650 and keeps an Outperform rating on the shares as part of a broader research note indicating that the firm is positive on 2025 for the MedTech sector. This year offers an abundance of growth catalysts across new launches, key products making progress towards regulatory approval, and notable trials reading out through the year, with hot segments that include robotic-assisted surgery, pulsed field ablation, insulin pumps, and new AI-enabled functionality across medtech segments, the analyst tells investors in a research note. The underlying medtech procedures volumes are strong, end markets are healthy, and favorable pricing dynamics should continue through 2025, the firm added.